Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Amgen
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:Timothy_P._Walbert
|
| gptkbp:focusArea |
rare diseases
inflammation |
| gptkbp:foundedYear |
2008
|
| gptkbp:founder |
gptkb:Timothy_P._Walbert
|
| gptkbp:fullName |
Horizon Therapeutics plc
|
| gptkbp:headquartersLocation |
gptkb:Dublin,_Ireland
|
| https://www.w3.org/2000/01/rdf-schema#label |
HZNP
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableProduct |
gptkb:Krystexxa
gptkb:Procysbi gptkb:Ravicti gptkb:Tepezza |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:HZNP
|
| gptkbp:website |
https://www.horizontherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Horizon_Pharma
gptkb:Nasdaq:_HZNP |
| gptkbp:bfsLayer |
8
|